Ciprian Jauca

🆕 TI Therapeutics Letter 153 🚨 Triple therapy for #COPD: Understanding evidence is complicated: ti.ubc.ca/letter153 Current evidence doesn't support first-line triple tx in treatment-naïve COPD patients, nor routinely adding ICS for people already using LAMA/LABA inhaler

TI Methods Speaker Series webinar: Evaluating study registration & result reporting of trials conducted in 🇨🇦 REGISTER NOW ➡️ ti.ubc.ca/trials Mohsen Alayche discusses his recent paper, which found significant deficiencies in Open Science, capturing global media interest

🎺 #ResearchMethods webinar recording! #Preprints: Catalyzing Equity and Integrity in Scientific Discourse ti.ubc.ca/2024/05/29/pre… Exploring how pre-prints foster transparency + accelerate scientific progress Considering necessary safeguards to maintain research integrity

🎺 TOMORROW (8 May @ noon PDT) #Deprescribing webinar: Antidepressant withdrawal effects & how to safely stop🛑 ✅Maudsley approach to deprescribing #antidepressants ✅Distinguishing withdrawal effects ✅Hyperbolic tapering Speaker: @markhoro Register: ti.ubc.ca/deprescribing-…

7/ What should I tell my patients about #Paxlovid for new-onset #COVID19? For most people with COVID-19, Paxlovid will: ✖️NOT make you feel better faster ✖️NOT lower your chance of dying or going to hospital 👉🏽Full Letter + patient materials: ti.ubc.ca/letter149 #PatientEd

🧵How useful is #Paxlovid for #COVID19 in 2024? 1/ New clinical trials evidence shows nirmatrelvir-ritonavir (Paxlovid) has relatively limited effectiveness for most people with new-onset COVID-19 infection 👉🏽 ti.ubc.ca/letter149 #MedEd #COVID #prescribing #overtreatment

🎺TI Therapeutics Letter 149: How useful is #Paxlovid in 2024? ti.ubc.ca/letter149 In people at LOWER risk: 🤒Doesn't shorten symptoms 🏥Doesn't ↘️ risk of hospitalization or death In people at HIGHER risk: ↘️reduces hospitalization w/ #COVID19 & risk of death #MedEd

Who needs #Paxlovid now? New guidelines suggest only highest-risk groups should get #COVID19 drug. Recommendations for provincial drug plans feature narrower definition of who should qualify, by @LaurenPelley cbc.ca/news/health/pa… via @cbcnews

🆕#Deprescribing webinar: Antidepressant withdrawal effects & how to safely stop them🛑 ✅Maudsley approach to deprescribing #antidepressants ✅Distinguishing withdrawal effects ✅Hyperbolic tapering Speaker: @markhoro Register: ti.ubc.ca/deprescribing-… #medsafety #MedEd

🆕UBC TI #ResearchMethods webinar recording 😍 Professor @StephenSenn's overview of the history of research synthesis: ti.ubc.ca/research-synth… #EvidenceSynthesis #MetaAnalysis #ResearchSynthesis @rlmcelreath @_MiguelHernan

🆕Our latest #Deprescribing webinar recording is now available! 💊 Reassessment of drug therapies 🫱🏿‍🫲🏽 Approaches to patient-prescriber collaboration ⚠️ Signs+symptoms after medication changes ti.ubc.ca/deprescribing-6 #MedEd #ptsafety #prescribing

Canadians need independent information and evaluation of drugs - Sign the Petition! chng.it/kDNCWJn2 via @CdnChange

Stop the closure of the CPSBC Library - Sign the Petition! chng.it/q56gDwSr via @CdnChange

🆕 TI #ResearchMethods webinar 😍 Professor Stephen Senn's overview of the history of #ResearchSynthesis 🗓️27 March @ Noon Pacific 🕛 👉🏽REGISTER: ti.ubc.ca/research-synth… #EvidenceSynthesis #MetaAnalysis

🆕UBC TI Therapeutics Letter 1⃣4⃣6⃣: #Apixaban is safer and more effective than rivaroxaban for non-valvular atrial fibrillation 👉🏽ti.ubc.ca/letter146 #MedEd #medsafety #prescribing #DOACs #NVAF

🎺We are thrilled to welcome our newest TI member, Dr. Siyana Kurteva!🤩 Siyana is an epidemiologist focused on generating observational research using best practices to improve #prescribing and #medsafety issues 👉🏽ti.ubc.ca/siyana-kurteva #WelcomeSiyana

🆕 #ResearchMethods WEBINAR! 😍 📊 👨🏾‍🏫 How can we address overlap of primary studies in overviews? Find out at our 28 Feb Methods Speaker Series webinar 👇🏽 Speaker: Dr. Javier Bracchiglione @JBracchiglione REGISTER here: ti.ubc.ca/overviews2024 #ResearchonResearch #Overviews

📢 Online WORKSHOP 📢 Intro to #MachineLearning in Python Classification & clustering models: ✅Applications in machine learning ✅Training models for real-world data sets ✅Interpret + analyze results 🎙️Dr. Shayan Fahimi 🖊️Register: ti.ubc.ca/31-jan-2024 #ResearchMethods

🆕#HTN Protocol publication alert 🚨 #Riboflavin supplements for #BloodPressure lowering in adults Our @CochraneLibrary review will assess the efficacy and safety of riboflavin supplements for lowering systolic and diastolic blood pressure: doi.org/10.1002/146518…

🚨Calling all meta-analysts! 🚨 Our November 29 UBC TI Methods Speaker Series webinar looks at Likelihood Ratio #MetaAnalysis (LRMA) Speaker: Dr. Colin Dormuth @ColinDormuth Register: ti.ubc.ca/lrma #ResearchMethods